{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:11Z","timestamp":1792787891292,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca T\u00fcrkiye"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This cost of illness study aimed to determine economic burden of short-acting \u03b22-agonist (SABA) overuse in T\u00fcrkiye from payer perspective with respect to the updated GINA 2022 treatment recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 3,034,879 asthma patients comprised the study population, via estimations extrapolated from the T\u00fcrkiye arm of the global SABINA III study. The economic burden (costs related to the drug use and severe exacerbations) was compared in subgroups of overall (\u2265\u20090 canisters\/year) vs. GINA-recommended (0\u20132 canisters\/year, hypothetical population) SABA use and in subgroups of appropriate use (0\u20132 canisters\/year, real population) vs. overuse (\u2265\u20093 canisters\/year) of SABA with extrapolation of SABINA T\u00fcrkiye data to the T\u00fcrkiye asthma population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Recommended SABA use was predicted to prevent 127,505 of 157,512 severe exacerbations per year in mild asthma patients and 2,668,916 of 3,262,800 severe exacerbations per year in moderate-severe asthma patients. Annual cost burden of not applying recommended SABA use (overall [\u2265\u20090 canisters\/year] vs. GINA-recommended [0\u20132 canisters\/year] SABA use) in mild asthma and moderate-severe asthma patients was calculated to be \u20ac20.43 million and \u20ac427.65 million in terms of severe exacerbations, and to be \u20ac829,352 and \u20ac7.20 million in terms of drug costs, respectively. The total annual economic burden arising from not applying recommended SABA use was estimated to be \u20ac456.11 million. Appropriate use (0\u20132 canisters\/year) vs. overuse (\u2265\u20093 canisters\/year) of SABA was associated with decreased frequency of severe exacerbations per year in mild asthma (from 129,878 to 27,634) and moderate-severe asthma (from 2,834,611 to 428,189) patients. SABA overuse in mild and moderate-severe asthma patients was estimated to yield an additional annual cost of \u20ac16.38 million and \u20ac385.59 million, respectively in terms of severe exacerbations, and a total \u20ac11.30 million additional drug cost. The overall annual economic burden arising from SABA overuse was estimated to be \u20ac413.27 million.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The estimated annual total economic burden arising from not applying recommended SABA use (\u20ac456.11 million) and SABA overuse (\u20ac413.27 million) with respect to the updated GINA 2022 treatment recommendations indicates the substantial cost burden of SABA overuse to the Turkish National Health System, corresponding up to 26% of the total direct cost of asthma reported in our country.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-024-03327-9","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T10:03:41Z","timestamp":1729505021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in T\u00fcrkiye: a cost analysis with respect to the updated GINA treatment recommendations"],"prefix":"10.1186","volume":"24","author":[{"given":"Arzu","family":"Yorganc\u0131o\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurtulu\u015f","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceyhun","family":"Cura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u011fit","family":"Yaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melda","family":"Din\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simten","family":"Malhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SABINA T\u00fcrkiye Study Group*","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"K\u0131z\u0131l\u0131rmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nejat","family":"Alt\u0131nta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smet","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fclin","family":"\u00c7a\u011fatay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilun","family":"Gemicio\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"\u0130nce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u0131v\u0131lc\u0131m","family":"O\u011fuz\u00fclgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dil\u015fad","family":"Mungan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00fcsun","family":"Kalpakl\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Ba\u00e7\u00e7\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Altunta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferda \u00d6ner","family":"Erkekol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl","family":"Karakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Fuat","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Damado\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"Hanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersoy","family":"Altunok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adviye","family":"\u00d6zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel At\u0131\u015f","family":"Nayc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demet Polat","family":"Yulu\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gazi","family":"G\u00fclba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mecit","family":"S\u00fcerdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Yormaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Ceylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Erge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"\u00c7illi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berat Celil","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuat","family":"Erel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Sevin\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceyda","family":"Anar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Ediger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclseren","family":"Pekbak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcge","family":"Erbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"11 Suppl 7","key":"3327_CR1","first-page":"S11","volume":"111","author":"FT Ishmael","year":"2011","unstructured":"Ishmael FT. The inflammatory response in the pathogenesis of asthma. J Am Osteopath Assoc. 2011;111(11 Suppl 7):S11\u20137.","journal-title":"J Am Osteopath Assoc"},{"key":"3327_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.rmed.2019.04.024","volume":"152","author":"A Mulgirigama","year":"2019","unstructured":"Mulgirigama A, Barnes N, Fletcher M, Pedersen S, Pizzichini E, Tsiligianni I. A review of the burden and management of mild asthma in adults - Implications for clinical practice. Respir Med. 2019;152:97\u2013104.","journal-title":"Respir Med"},{"key":"3327_CR3","unstructured":"Global Asthma Network (GAN): The Global Asthma Report. http:\/\/globalasthmareport.org\/ (2022). Accessed 11 May 2023."},{"key":"3327_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1471-2458-12-204","volume":"12","author":"T To","year":"2012","unstructured":"To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.","journal-title":"BMC Public Health"},{"issue":"1","key":"3327_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12890-018-0621-9","volume":"18","author":"H Tarraf","year":"2018","unstructured":"Tarraf H, Aydin O, Mungan D, Albader M, Mahboub B, Doble A, et al. Prevalence of asthma among the adult general population of five Middle Eastern countries: results of the SNAPSHOT program. BMC Pulm Med. 2018;18(1):68.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"3327_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","volume":"205","author":"HK Reddel","year":"2022","unstructured":"Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022;205(1):17\u201335.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3327_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","volume":"33","author":"ML Levy","year":"2023","unstructured":"Levy ML, Bacharier LB, Bateman E, Boulet LP, Brightling C, Buhl R, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33(1):7.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"5","key":"3327_CR8","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1183\/09031936.00100113","volume":"43","author":"L Laforest","year":"2014","unstructured":"Laforest L, Licaj I, Devouassoux G, Chatte G, Martin J, Van Ganse E. Asthma drug ratios and exacerbations: claims data from universal health coverage systems. Eur Respir J. 2014;43(5):1378\u201386.","journal-title":"Eur Respir J"},{"issue":"8","key":"3327_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJM199202203260801","volume":"326","author":"WO Spitzer","year":"1992","unstructured":"Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326(8):501\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"3327_CR10","doi-asserted-by":"publisher","first-page":"2003051","DOI":"10.1183\/13993003.03051-2020","volume":"57","author":"PM O'Byrne","year":"2021","unstructured":"O\u2019Byrne PM, Reddel HK, Beasley R. The management of mild asthma. Eur Respir J. 2021;57(4):2003051.","journal-title":"Eur Respir J"},{"issue":"10","key":"3327_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11882-022-01038-x","volume":"22","author":"ZF Ozseker","year":"2022","unstructured":"Ozseker ZF, Aksu K, Mutlu LC, Mutlu P, Ozturk C. Turkish Respiratory Society, Asthma, Allergic Respiratory Disease Scientific Committee. Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction-Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS\/LABA. Curr Allergy Asthma Rep. 2022;22(10):123\u201334.","journal-title":"Curr Allergy Asthma Rep."},{"issue":"8","key":"3327_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-028995","volume":"9","author":"EA Azzi","year":"2019","unstructured":"Azzi EA, Kritikos V, Peters MJ, Price DB, Srour P, Cvetkovski B, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey. BMJ Open. 2019;9(8): e028995.","journal-title":"BMJ Open"},{"key":"3327_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.rmed.2017.08.014","volume":"131","author":"JM FitzGerald","year":"2017","unstructured":"FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135\u201340.","journal-title":"Respir Med"},{"issue":"3","key":"3327_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.chest.2016.10.028","volume":"151","author":"M Sadatsafavi","year":"2017","unstructured":"Sadatsafavi M, Tavakoli H, Lynd L, FitzGerald JM. Has asthma medication use caught up with the evidence? A 12-year population-based study of trends. Chest. 2017;151(3):612\u20138.","journal-title":"Chest"},{"issue":"3","key":"3327_CR15","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s12325-020-01233-0","volume":"37","author":"C Janson","year":"2020","unstructured":"Janson C, Menzies-Gow A, Nan C, Nuevo J, Papi A, Quint JK, et al. SABINA: An Overview of Short-Acting \u03b22-Agonist Use in Asthma in European Countries. Adv Ther. 2020;37(3):1124\u201335.","journal-title":"Adv Ther"},{"issue":"1","key":"3327_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1183\/20734735.008914","volume":"11","author":"ML Levy","year":"2015","unstructured":"Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe. 2015;11(1):14\u201324.","journal-title":"Breathe"},{"issue":"4","key":"3327_CR17","doi-asserted-by":"publisher","first-page":"1901872","DOI":"10.1183\/13993003.01872-2019","volume":"55","author":"BI Nwaru","year":"2020","unstructured":"Nwaru BI, Ekstr\u00f6m M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting \u03b22-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872.","journal-title":"Eur Respir J"},{"issue":"7","key":"3327_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/17476348.2022.2099841","volume":"16","author":"A Al Zaabi","year":"2022","unstructured":"Al Zaabi A, Busaidi N, Al Mutairy S, Yorganc\u0131o\u011flu A, Aksu K, Al-Jahdali H, et al. Overprescription of short-acting \u03b22-agonists is associated with poor asthma symptom control: results from five Middle Eastern countries included in the SABINA International (III) study. Expert Rev Respir Med. 2022;16(7):833\u201347.","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"3327_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/jcm9040921","volume":"9","author":"A Kaplan","year":"2020","unstructured":"Kaplan A, Mitchell PD, Cave AJ, Gagnon R, Foran V, Ellis AK. Effective asthma management: is it time to let the air out of SABA? J Clin Med. 2020;9(4):921.","journal-title":"J Clin Med"},{"issue":"6","key":"3327_CR20","doi-asserted-by":"publisher","first-page":"1901046","DOI":"10.1183\/13993003.01046-2019","volume":"53","author":"HK Reddel","year":"2019","unstructured":"Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046.","journal-title":"Eur Respir J"},{"issue":"2","key":"3327_CR21","doi-asserted-by":"publisher","first-page":"1901858","DOI":"10.1183\/13993003.01858-2019","volume":"55","author":"CS Cabrera","year":"2020","unstructured":"Cabrera CS, Nan C, Lindarck N, Beekman MJHI, Arnetorp S, van der Valk RJP. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting \u03b22-agonist use in asthma. Eur Respir J. 2020;55(2):1901858.","journal-title":"Eur Respir J"},{"issue":"10","key":"3327_CR22","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1007\/s12325-020-01444-5","volume":"37","author":"CI Bloom","year":"2020","unstructured":"Bloom CI, Cabrera C, Arnetorp S, Coulton K, Nan C, van der Valk RJP, et al. Asthma-Related Health Outcomes Associated with Short-Acting \u03b22-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. Adv Ther. 2020;37(10):4190\u2013208.","journal-title":"Adv Ther"},{"issue":"5","key":"3327_CR23","doi-asserted-by":"publisher","first-page":"2101402","DOI":"10.1183\/13993003.01402-2021","volume":"59","author":"ED Bateman","year":"2022","unstructured":"Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, et al. Short-acting \u03b22-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022;59(5):2101402.","journal-title":"Eur Respir J"},{"issue":"1","key":"3327_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12890-022-02008-9","volume":"22","author":"A Yorganc\u0131o\u011flu","year":"2022","unstructured":"Yorganc\u0131o\u011flu A, Aksu K, Nayc\u0131 SA, Ediger D, Mungan D, G\u00fcl U, et al. Short-acting \u03b22-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III. BMC Pulm Med. 2022;22(1):216.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"3327_CR25","first-page":"111","volume":"2","author":"H Turktas","year":"2018","unstructured":"Turktas H, Bavbek S, Sekerel B, Oksuz E, Malhan S. Economic Burden of Adult Asthma in Turkey: A Cost of Illness Study from Payer Perspective. J Respir Med. 2018;2(1):111.","journal-title":"J Respir Med"},{"issue":"2","key":"3327_CR26","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1016\/j.jaci.2010.10.042","volume":"127","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V, Globe DR, Lin SL. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2011;127(2):3639-9.e1-3.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"3327_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.23822\/EurAnnACI.1764-1489.149","volume":"53","author":"S Bavbek","year":"2021","unstructured":"Bavbek S, Malhan S, Mungan D, Misirligil Z, Erdinc M, Gemicioglu B, et al. Economic burden of severe asthma in Turkey: a cost of illness study from payer perspective. Eur Ann Allergy Clin Immunol. 2021;53(3):128\u201337.","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"4","key":"3327_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.rmed.2010.10.011","volume":"105","author":"S Bavbek","year":"2011","unstructured":"Bavbek S, Mungan D, T\u00fcrkta\u015f H, M\u0131s\u0131rl\u0131gil Z, Gemicio\u011flu B. ADVISE Study Group A. cost-of-illness study estimating the direct cost per asthma exacerbation in Turkey. Respir Med. 2011;105(4):541\u20138.","journal-title":"Respir Med."},{"issue":"2","key":"3327_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.18176\/jiaci.0767","volume":"33","author":"A Valero","year":"2023","unstructured":"Valero A, Molina J, Nuevo J, Simon S, Capel M, Sicras-Mainar A, et al. Economic Consequences of the Overuse of Short-Acting \u00df-Adrenergic Agonists in the Treatment of Asthma in Spain. J Investig Allergol Clin Immunol. 2023;33(2):109\u201318.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"3327_CR30","doi-asserted-by":"publisher","first-page":"BJGPO.2030.015","DOI":"10.3399\/BJGPO.2023.0015","volume":"7","author":"D Attar-Zadeh","year":"2023","unstructured":"Attar-Zadeh D, Capstick T, Leese D, Arnetorp S, Rapsomaniki E, Da Costa KP, et al. Healthcare costs associated with short-acting \u03b22-agonists in asthma: observational UK SABINA study. BJGP Open. 2023;7(3):BJGPO.2030.015.","journal-title":"BJGP Open."},{"key":"3327_CR31","unstructured":"Republic of Turkey Social Security Institution: The Medical Enforcement Declaration. https:\/\/www.resmigazete.gov.tr\/fihrist?tarih=2022-08-25&mukerrer=1 (2022). Accessed 13 May 2023."},{"issue":"1","key":"3327_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000338998","volume":"160","author":"S Accordini","year":"2013","unstructured":"Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol. 2013;160(1):93\u2013101.","journal-title":"Int Arch Allergy Immunol"},{"key":"3327_CR33","unstructured":"Global Asthma Network (GAN): The Global Asthma Report. http:\/\/ www. globa lasth marep ort. org\/ (2018). Accessed 15 Apr 2021."},{"key":"3327_CR34","doi-asserted-by":"publisher","first-page":"A560","DOI":"10.1016\/j.jval.2016.09.1238","volume":"19","author":"C Nordon","year":"2016","unstructured":"Nordon C, Aubier M, Thabut G, Grimaldi-Bensouda L, Amzal B, Pribil C, et al. The Burden of Severe Asthma in France. Value Health. 2016;19:A560\u20131.","journal-title":"Value Health"},{"key":"3327_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2466-9-24","volume":"9","author":"K Bahadori","year":"2009","unstructured":"Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"3327_CR36","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jaci.2016.12.001","volume":"139","author":"T Haahtela","year":"2017","unstructured":"Haahtela T, Herse F, Karjalainen J, Klaukka T, Linna M, Leskel\u00e4 RL, et al. The Finnish experience to save asthma costs by improving care in 1987\u20132013. J Allergy Clin Immunol. 2017;139(2):408-14.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"3327_CR37","doi-asserted-by":"publisher","first-page":"A593","DOI":"10.1016\/j.jval.2014.08.2040","volume":"17","author":"H Turktas","year":"2014","unstructured":"Turktas H, Bavbek S, Malhan S. The Direct Cost of Asthma in Turkey. Value Health. 2014;17(7):A593.","journal-title":"Value Health"},{"key":"3327_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/JAA.S350393","volume":"15","author":"S Avdeev","year":"2022","unstructured":"Avdeev S, Voznesenskiy N, Boldina M, Ignatova G, Kostina N, Kulbaisov A, et al. SABA Overuse in Russia - Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study. J Asthma Allergy. 2022;15:371\u20139.","journal-title":"J Asthma Allergy"},{"issue":"1","key":"3327_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41533-021-00231-1","volume":"31","author":"C-Y Wang","year":"2021","unstructured":"Wang C-Y, Lai C-C, Wang Y-H, Wang H-C. The prevalence and outcome of short-acting \u03b22-agonists overuse in asthma patients in Taiwan. NPJ Prim Care Respir Med. 2021;31(1):19.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"1","key":"3327_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40733-022-00085-5","volume":"8","author":"A Alzaabi","year":"2022","unstructured":"Alzaabi A, Al Busaidi N, Pradhan R, Shandy F, Ibrahim N, Ashtar M, et al. Over-prescription of short-acting \u03b22-agonists and asthma management in the Gulf region: a multicountry observational study. Asthma Res Pract. 2022;8(1):3.","journal-title":"Asthma Res Pract"},{"issue":"4","key":"3327_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283876","volume":"18","author":"ZC Loh","year":"2023","unstructured":"Loh ZC, Hussain R, Balan S, Saini B, Muneswarao J, Ong SC, et al. Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting \u03b22-agonists: A systematic review. PLoS ONE. 2023;18(4): e0283876.","journal-title":"PLoS ONE"},{"issue":"2","key":"3327_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.rmed.2011.09.012","volume":"106","author":"JA Douglass","year":"2012","unstructured":"Douglass JA, Goeman DP, McCarthy EA, Sawyer SM, Aroni RA, Stewart K, et al. Over-the-counter \u03b22-agonist purchase versus script: a cross-sectional study. Respir Med. 2012;106(2):223\u20139.","journal-title":"Respir Med"},{"issue":"9","key":"3327_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016688","volume":"7","author":"HK Reddel","year":"2017","unstructured":"Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7(9): e016688.","journal-title":"BMJ Open"},{"issue":"suppl 63","key":"3327_CR44","first-page":"OA2107","volume":"54","author":"M Kupczyk","year":"2019","unstructured":"Kupczyk M, Barg W, Bochenek G, Bro\u017cek G, Brzostek D, D\u0105browiecki P, et al. Late Breaking Abstract - Overprescription of short-acting beta2-agonists in asthma management? Pharmacy reports from 91,673 patients in Poland. Eur Respir J. 2019;54(suppl 63):OA2107.","journal-title":"Eur Respir J."},{"issue":"2","key":"3327_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.opresp.2023.100232","volume":"5","author":"J Molina","year":"2023","unstructured":"Molina J, Plaza V, Nuevo J, Guti\u00e9rrez M, Sicras-Mainar A, Valero A. Clinical Consequences of the Overuse of Short-Acting \u03b22-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study. Open Respir Arch. 2023;5(2): 100232.","journal-title":"Open Respir Arch"},{"issue":"6","key":"3327_CR46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.anai.2021.01.024","volume":"126","author":"N Lugogo","year":"2021","unstructured":"Lugogo N, Gilbert I, Tkacz J, Gandhi H, Goshi N, Lanz MJ. Real-world patterns and implications of short-acting \u03b22-agonist use in patients with asthma in the United States. Ann Allergy Asthma Immunol. 2021;126(6):681-9.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"3327_CR47","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1007\/s12325-021-01772-0","volume":"38","author":"F Di Marco","year":"2021","unstructured":"Di Marco F, D\u2019Amato M, Lombardo FP, Micheletto C, Heiman F, Pegoraro V, et al. The burden of short-acting \u03b22-agonist use in asthma: is there an Italian case? An update from SABINA program. Adv Ther. 2021;38(7):3816\u201330.","journal-title":"Adv Ther"},{"issue":"8","key":"3327_CR48","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1016\/j.jaip.2020.03.013","volume":"8","author":"S Amin","year":"2020","unstructured":"Amin S, Soliman M, McIvor A, Cave A, Cabrera C. Usage patterns of short-acting \u03b22-agonists and inhaled corticosteroids in asthma: a targeted literature review. J Allergy Clin Immunol Pract. 2020;8(8):2556-64.e8.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"3327_CR49","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jaip.2022.02.047","volume":"10","author":"JK Quint","year":"2022","unstructured":"Quint JK, Arnetorp S, Kocks JWH, Kupczyk M, Nuevo J, Plaza V, et al. Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America. J Allergy Clin Immunol Pract. 2022;10(9):2297-309.e10.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"3327_CR50","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.anai.2012.08.014","volume":"109","author":"RH Stanford","year":"2012","unstructured":"Stanford RH, Shah MB, D\u2019Souza AO, Dhamane AD, Schatz M. Short-acting \u03b2-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3327_CR51","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/02770903.2020.1841223","volume":"59","author":"E Azzi","year":"2022","unstructured":"Azzi E, Kritikos V, Peters M, Price D, Cvetkovski B, Alphonse PS, et al. Perceptions, attitudes, and behaviors of short-acting beta2 agonist users: an Australian cross-sectional community pharmacybased study. J Asthma. 2022;59(1):178\u201388.","journal-title":"J Asthma"},{"key":"3327_CR52","doi-asserted-by":"publisher","DOI":"10.56801\/seejph.vi.74","author":"M Jakovljevic","year":"2023","unstructured":"Jakovljevic M, Souliotis K. Pharmaceutical expenditure changes in Serbia and Greece during the global economic recession. South Eastern European Journal of Public Health. 2023. https:\/\/doi.org\/10.56801\/seejph.vi.74.","journal-title":"South Eastern European Journal of Public Health"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03327-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T02:02:52Z","timestamp":1729648972000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03327-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3327"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03327-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this cost-analysis study, using the datasets already generated in the previously published SABINA T\u00fcrkiye study which was approved by Manisa Celal Bayar University Ethics Committee (Date of Approval: 06\/08\/2019, Protocol No: E.46053) and Republic of Turkey Ministry of Health Turkish Medicines and Medical Devices Agency (Date of Approval: 20\/08\/2019, Protocol No: 66175679\u2013514.05.01-E.127964).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AY has received research grants from MSD, AstraZeneca and Sanofi as a principal investigator\/collaborator, received honoraria from AstraZeneca, Abdi \u0130brahim, GSK, Novartis Sandoz, Sanofi and Chiesi, and served as a consultant\/advisory member for AstraZeneca, GSK, Novartis, Sanofi, Chiesi and Deva; KA has received research support from Sanofi, AstraZeneca, Health Institutes of T\u00fcrkiye (TUSEB) and received consulting or scientific speaking fees from AstraZeneca, GlaxoSmithKline, Novartis, Sandoz, Chiesi, \u0130brahim Etem, Abdi \u0130brahim, Deva and Acino; CC is an employee of AstraZeneca T\u00fcrkiye; YY is an employee of AstraZeneca T\u00fcrkiye; MD is an employee of AstraZeneca T\u00fcrkiye; SM has received research grants from AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"524"}}